Uzbekistan is set to upgrade two major substations in Tashkent through a new contract with a Chinese company. The project ...

ASCO 2025 may be over, but the insights are just beginning. This “Spotlight On” page is your hub for ongoing post-event coverage, including expert interviews, key takeaways, and video content ...

A year ago, enthusiasm for a new generation of cancer immunotherapies targeting TIGIT started to wane, after Roche’s tiragolumab was hit by two failed studies in lung cancer. Fa ...

(UroToday.com) The 2025 ASCO annual meeting featured a urothelial carcinoma rapid oral abstract session and a presentation by Dr. Xinan Sheng discussing results from a phase 1b/2 study assessing ...